Clerk of the House of Representatives
Legislative Resource Center
135 Cannon Building
Washington, DC 20515
http://lobbyingdisclosure.house.gov 		Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510
http://www.senate.gov/lobby
LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Organization/Lobbying Firm Self Employed Individual
HealthCare Institute of New Jersey

2. Address

Address1
10 W. Lafayette Street
 Address2
​
City
Trenton
 State
NJ
 Zip Code
08608
 Country
USA

3. Principal place of business (if different than line 2)

City
​
State
​
Zip Code
​
Country
​
4a. Contact Name b. Telephone Number c. E-mail
​Mr.
​Steve Issenman
​9083479418
​issenman@hinj.org
5. Senate ID#
​75251-12
7. Client Name Self Check if client is a state or local government or instrumentality
​HealthCare Institute of New Jersey
6. House ID#
​360350000
TYPE OF REPORT 8. Year
​2026
 Q1 (1/1 - 3/31) Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report Termination Date
​
11. No Lobbying Issue Activity
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13
12. Lobbying 13. Organizations
INCOME relating to lobbying activities for this reporting period was: EXPENSE relating to lobbying activities for this reporting period were:
Less than $5,000
Less than $5,000
$5,000 or more $
​
$5,000 or more $
​50,973.00
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.
Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature
Digitally Signed By: Steve Issenman
 Date
4/10/2026 12:57:08 PM

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

Generally promoting awareness of the biopharmaceutical and medical technology sectors.
Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere.
Generally supporting intellectual property rights.
Generally opposing various legislative and executive efforts to impose an international price index.
Generally promoting awareness of increasing antimicrobial/antifungal resistance.
Supporting the extension of the SBIR program.
Generally supporting changes to the 340B program.
Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients.
Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations.
Opposing proposed FTC changes to non-compete clauses.
Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1414).
Supporting the modernization of prescribing information to allow digital in lieu of printed information, H.R. 4132 and S. 2027.
Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691 in the previous Congress).
Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369 in the previous Congress).
Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 in the previous Congress).
Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880 in the previous Congress).
Supporting the PASTEUR Act (H.R. 2940 and S. 1355 in the previous Congress).
Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407 in the previous Congress).
Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764 in the previous Congress).
Supporting the Rare Pediatric Disease Priority Review Voucher Act (H.R. 1262 and S. 932).
Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 1672).
Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283 in the previous Congress).
Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 1492 and S. 832).
Supporting "cap and smooth" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses.
Opposing pricing policies related to "Most Favored Nation" proposals and indexing to international prices.
Opposing tariffs on pharmaceutical and medical device products.
Opposing CMSs proposed interpretation of a Qualifying Single Source Drug (QSSD).
Generally providing thoughts on federal data privacy transparency and security policies.
Submitting comments opposing proposed changes to bona fide fee structures.
Generally opposing CMMI's demonstration project on prior authorization in the Medicare program.
Supporting the RESULTS Act, HR 5269 and S.2761.
Opposing CMS GUARD and GLOBE pricing model proposals.
Opposing HR 3375 and S 1587, "Most Favored Nation" legislation.
Supporting the PBM FAIR Act, H.R. 68937 and S. 3549.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Steve
Issenman
​
Cong. Page (87-88), Congressional Aide (1990's)

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address
​
City
​
State
​
Zip Code
​
Country
​

21. Client new principal place of business (if different than line 20)

City
​
State
​
Zip Code
​
Country
​

22. New General description of client’s business or activities

​

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name
Last Name
Suffix
First Name
Last Name
Suffix
1
​
​
​
3
​
​
​
2
​
​
​
4
​
​
​

ISSUE UPDATE

24. General lobbying issue that no longer pertains

​
​
​
​
​
​
​
​
​

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name Address Principal Place of Business
(city and state or country)
Street Address
City State/Province Zip Country
City
State Country

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1 2 3

FOREIGN ENTITIES

27. Add the following foreign entities:

Name Address Principal place of business
(city and state or country) 		Amount of contribution for lobbying activities Ownership percentage in client
Street Address
City State/Province Country
City
State Country
%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1 3 5
2 4 6

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

Lobbyist Name Description of Offense(s)